Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
$7.49
-$0.31(-5.78%)
At close: 4:00 PM EST
$7.49
-$0.31(-5.78%)
Day’s Range― - ―
52-Week Range$2.88 - $22.91
Previous CloseN/A
Volume146.35K
Average Volume (3M)196.83K
Market Cap
$267.80M
Enterprise Value-$140.49M
Total Cash (Recent Filing)$285.78M
Total Debt (Recent Filing)$7.13M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 19, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding35,850,037
10 Day Avg. Volume197,907
30 Day Avg. Volume196,830
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.19
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap-0.52
Enterprise Value/Revenue-23.74
Enterprise Value/Gross Profit-36.37
Enterprise Value/Ebitda1.80
Forecast
1Y Price Target
$10.00Price Target Upside33.51% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's balance sheet is expected to fund operations through 2029, past several value-creating inflection points.
Investor InterestCompany stands to benefit from recent investor interest in NLRP3.
Market OpportunitiesNLRP3 inhibitors may potentially complement GLP-1 therapies for patients with high cardiovascular risk or liver diseases, offering new market opportunities.
Bears Say
Financial LossBioAge reported a net loss of $20.2 million for the third quarter, which was worse than the estimated net loss.
Operating ExpensesHigher-than-expected R&D expenses primarily drove the difference between estimated and reported operating results.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $2.88 and its highest was $22.91 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $267.80M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 127 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.584 by $0.024.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.76.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 35,850,037 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.584. Following the earnings report the stock price went down -2.811%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
BioAge Labs, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (33.51% Upside)
$10.00 (33.51% Upside)
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-77.46%
12-Months-Change
Fundamentals
Return on Equity
-25.64%
Trailing 12-Months
Asset Growth
95.95%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA) is a biotechnology company focused on developing innovative therapies aimed at extending healthy human lifespan by targeting the molecular pathways associated with aging. The company leverages its proprietary platform to identify and validate drug targets that can modulate key biological processes involved in aging. BioAge's core products include a pipeline of therapeutic candidates designed to treat age-related diseases and improve healthspan.
BIOA Stock 12 Month Forecast
Average Price Target
$10.00
▲(33.51% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
9.03% Insiders
5.72% Mutual Funds
43.25% Other Institutional Investors
34.87% Public Companies and
Individual Investors